We investigated the mechanism of retinoic acid receptor (RAR) b2 gene silencing in breast cancer cells. Transfection experiments indicated that MCF-7 cells transactivate an exogenous b2 promoter (71470/+156) to the same extent as MTSV1.7 breast epithelial cells, which express endogenous RARb2. This was true even in the context of replicated chromatin, suggesting a cisacting rather than a trans-acting defect. Cytosine methylation, a cis-acting DNA modi®cation, has been implicated in RARb2 silencing in cancer cells. Upon bisul®te genomic sequencing, we found that 3 CpG sites in the b2 RARE region were variably methylated in MCF-7 cells but were not methylated in MTSV1.7 cells or in 2 MDA-MB-231 subclones that diered in RARb2 expression (high in clone A2, low in clone A4). However, the 5'-UTR region was hypermethylated in clone A4 relative to clone A2 cells. Following 5-azacytidine treatment, RA and trichostatin A markedly induced RARb2 expression in MCF-7 cells but not in MDA-MB-231 clone A4 cells. A b2 RARE reporter construct in which the methylation-susceptible cytosines in the sense strand were replaced by thymine displayed marked loss of activity in a replicated chromatin-dependent manner. We conclude that cytosine methylation contributes to RARb2 gene silencing in MCF-7 cells and that methylation of the RARE region may be particularly important.
Retinoic acid (RA) is a vital signal for vertebrate development and for the maintenance of epithelial dierentiation. The biological actions of RA are mediated by all-trans retinoic acid receptors (RARa, b, g ) and 9-cis retinoic acid receptors (RXRa, b, g) , which are heterodimerizing ligand-dependent transcription factors that bind RA response elements (RAREs) characterized by PuGG(T)TCA direct repeats spaced by two or ®ve basepairs (Chambon, 1996; Mangelsdorf and Evans, 1995) . In its natural context, gene induction by RA requires chromatin remodeling (Dey et al., 1994) . This requirement is met, at least in part, by liganded RXR-RAR recruitment of a coactivator complex with histone acetylase activity (Xu et al., 1999) . In the absence of ligand, RXR-RAR repress transcription via recruitment of a corepressor complex that eects histone deacetylation, thus reinstating the closed chromatin state (Xu et al., 1999) .
DNA hypermethylation is a mechanism of transcriptional silencing that is implicated in parental gene imprinting, X chromosome inactivation, and endogenous retrovirus silencing (Tycko, 1997; Yoder et al., 1997) , as well as in the transcriptional silencing of tumor suppressor genes (Baylin et al., 1998) . Hypermethylation may occur within CpG islands or at isolated CpG sites, and in either case may be correlated with transcriptional inactivation. Transcriptional repression by hypermethylation is typically chromatindependent and may be mediated by the recruitment of histone deacetylase (Nan et al., 1998) or other mechanisms, including unfavorable nucleosomal positioning (Davey et al., 1997) .
RARb2 expression is downregulated in human breast cancer (Jing et al., 1996; Swisshelm et al., 1994; Xu et al., 1997) and RARb2 overexpression supports RA-induced growth suppression (Liu et al., 1996; Seewaldt et al., 1995) , suggesting that RARb2 inactivation may contribute to breast cancer development. The mechanism of RARb2 downregulation in breast cancer is not well understood. In lung cancer cell lines, both trans-acting and cis-acting transcriptional defects have been shown to occur Neel, 1995, 1998; Zhang et al., 1994) .
We wished to de®ne the mechanism responsible for the de®cit in RARb2 expression in breast cancer cells relative to normal human breast epithelial cells. Immortalized but non-tumorigenic MTSV1.7 human breast epithelial cells, like normal breast epithelial cells, express RARb2 upon RA induction (Jing et al., 1996) and were used as a suitable control. We ®rst compared the activity of 71470/+156 RARb2-LUC in MTSV1.7 and MCF-7 cells; both cell types displayed constitutive promoter activity and addition of 1 mM RA increased promoter activity two-and fourfold, respectively, resulting in comparable total activities (Figure 1a ). Since transiently-transfected promoters are associated with a rudimentary chromatin complex (Smith and Hager, 1997), we retested the activity of 71470/+156 RARb2-LUC after stable transfection. Using pools of *100 G418-resistant colonies, we obtained similar induction levels as after transient transfection, or ®vefold for MCF-7 (Figure 1b ) and *twofold for MTSV1.7 cells (data not shown). We also found that treatment with the histone deacetylase inhibitor Oncogene (2000) 19, 4066 ± 4070 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc trichostatin A (TSA) did not rescue endogenous RARb2 expression in MCF-7 cells (Figure 1c ). We conclude, in contrast to other work (Swisshelm et al., 1994) , that MCF-7 cells express the transcription factors and cofactors required to attain breast-speci®c levels of b2 promoter activity. However, we cannot exclude the possibility that a longer RARb2 template might reveal a relative transcriptional de®cit in MCF-7 cells (Baust et al., 1996; Moghal and Neel, 1998) . We established by genomic DNA sequencing that the b2 proximal promoter in MCF-7 and MDA-MB-231 clone A4 cells (another low RARb2 expressor) was not mutated.
Methylation of the RARb2 gene has been shown to repress its expression in DLD-1 colon carcinoma cells (CoÃ teÂ et al., 1998) . The b2 proximal promoter is particularly devoid of CG dinucleotides but there are three CpG sites strategically located in the b2 RARE region that, if methylated, could conceivably hinder promoter activity (sites 1, 2 and 3 in Figure 2a ). These sites are conserved in the murine b2 and human a2 promoters (Leroy et al., 1991) . Sites 2 and 3, along with sites in the 5'-UTR region, were found to be methylated in DLD-1 cells and to be demethylated by 5-aza-2'deoxycytidine treatment, which rescued RARb2 expression (CoÃ teÂ et al., 1998) . We performed bisul®te genomic sequencing to assess methylation of the b2 RARE region in breast cells. None of the three CpG sites were methylated in MTSV1.7 cells, whereas all three sites were methylated in MCF-7 cells ( Figure  2b ,c). Methylation was not homogenous, there being a prevalence for methylation of CpG sites 2 and 3 (Figure 2b ), as observed for DLD-1 cells (CoÃ teÂ et al., 1998) . We did not observe simultaneous methylation of all three sites; simultaneous methylation of sites 2 and 3 occurred with a frequency of 27%. To test if methylation heterogeneity was related to cellular heterogeneity, we performed a preliminary analysis of MCF-7 cell clones A and B, which diered markedly in the extent of methylation at a dierent locus (data not shown); as seen in Figure 2b , both clones evidenced b2 RARE methylation, again preferentially of sites 2 and 3 (the dierence in per cent methylation between parental, clone A, and clone B cells was not statistically signi®cant; Chi square analysis). We reported previously that RARb2 was expressed in MDA-MB-231 clone A2 but not in MDA-MB-231 clone A4 cells (Jing et al., 1996) . We found no evidence of b2 RARE methylation in either cell clone ( Figure 2b ). However, the 5'-UTR region was hypermethylated in A4 cells relative to A2 cells ( Figure 2d ).
Pretreatment with 5-azacytidine (azaC) for 2 days, followed by 24 h stimulation with TSA and RA, resulted in robust induction of RARb2 expression in MCF-7 cells and azaC was essential for this eect ( Figure 3a) ; similar results were obtained for MCF-7 clone A cells (data not shown). These results indicate that DNA methylation contributes, at least in part, to the RARb2 expression de®cit of MCF-7 cells. In contrast to these results, azaC in combination with RA and TSA did not have a signi®cant eect on RARb2 expression in MDA-MB-231 A4 cells, in which only the 5'-UTR (not the RARE) was methylated ( Figure  3b) . Additional experiments in which A4 cells were treated with azaC for 4 days also did not succeed in rescuing receptor expression, whereas other hypermethylated genes, e.g., ERa (Ferguson et al., 1995) , were partially reexpressed (data not shown). These results suggested that RARE methylation might have a stronger silencing eect than methylation elsewhere in the RARb2 gene.
To test the eect of methylation con®ned to the RARE, we ligated an in vitro methylated b2 RARE (Bartek et al., 1990) were transiently transfected with 5 mg 71470/+156 RARb2-LUC (Kruyt et al., 1991) , 5 mg pSG5-RARb2 and 0.1 mg pRLSV40 (internal control) then washed and treated with or without 1 mM RA for 24 h (all-trans RA was always used). Fire¯y and Renilla LUC activity were assayed with the dual LUC assay system (Promega). Similar results were obtained in the absence of RAR cotransfection. In this and all other transfection experiments, data shown is the mean+s.e.m. of biological triplicates. (b) MCF-7 cells were cotransfected with 10 mg 71470/+156 RARb2-LUC and 1 mg pSV2neo and selected in 500 mg/ml G418 medium. Cells were treated with 1 mM RA for 24 h and LUC activity normalized to protein content. RLU, Relative Light Units. (c) Cells were treated as shown (RA at 1 mM and TSA at 100 nM) for 24 h and mRNA blots prepared and probed as described (Jing et al., 1996) . Autoradiographs were exposed for 3 days (RARb2) or 16 h (GAPDH). Despite underloading, RARb2 mRNA could be detected in RA treated MTSV1.7 cells but not in RA or RA and TSA treated MCF-7 cells. The RA induction of RARb2 in MTSV1.7 cells was illustrated earlier (Jing et al., 1996) oligo into the HindIII site of pTKGH, placing it upstream of a minimal thymidine kinase (TK) promoter and the human growth hormone (GH) reporter gene. After transient transfection of the ligation mixture into SC115 cells (chosen for their high transfection eciency and growth rate), we observed strong RA induction of reporter activity with either wild-type or methylated RARE (Figure 4b ). To evaluate the activity of the methylated RARE in the context of replicated chromatin, we stably transfected the same constructs; however, bisul®te genomic sequencing revealed that RARE methylation was not propagated in vivo, precluding further progress along this line. As an alternative approach, we designed a mutant b2 RARE oligo in which the three CG dinucleotides in the top strand were replaced by TG dinucleotides (Figure 4a ; like methylated cytosine, thymine bears a methyl group in the ®ve position of the pyrimidine ring). The activity of the mutant RARE after transient transfection was lower than wild-type RARE but still quite strong (Figure 4b ). However, after stable transfection, a pool of4200 G418-resistant colonies transfected with the mutant RARE displayed a much weaker response to RA than a similar pool transfected with wild-type RARE (compare the ®rst two data columns for each construct in Figure 4c ). These results suggest that, in the context of chromatin, the mutant RARE cannot be properly activated. This is striking insofar as the mutation we made does not aect bases that contact the RXR-RAR heterodimer (Dey et al., 1994; Kurokawa et al., 1993) and does not alter the spacing between the direct repeats, or between these and the TATA box in the TK promoter. A relative de®cit in the activity of the mutant RARE persisted in the presence of TSA (Figure 4c ). The inhibitory eect of the CG to TG mutation was con®rmed using individual colonies. Thus, most (4/5) wild-type RARE clones showed robust activation by RA (between one and two orders of magnitude), whereas most (6/8) mutant RARE clones were poorly Bisul®te genomic sequencing of the b2 RARE region (sense strand). Open circles, non-methylated; closed circles, methylated cytosines. Each row corresponds to a dierent clone sequenced. Bisul®te genomic sequencing was carried out as described with some modi®cations (Clark et al., 1994; Frommer et al., 1992) . Brie¯y, 5 mg of XbaI-digested genomic DNA was denatured with 0.5 M NaOH at 758C for 15 min, deaminated with freshly prepared 4.0 M, pH 5.0 sodium metabisul®te (BDH, UK) and incubated at 558C for 8 h in a total volume of 1.2 ml under mineral oil. Desalting, desulfonation by alkali, neutralization and ethanol precipitation were as described (Frommer et al., 1992) . The DNA was resuspended in 50 ml H 2 O and fully-nested PCR carried out in a 50 ml reaction mixture of 106PCR buer, 1.2 mM MgCl 2 , 160 mM dNTPs, 0.4 mM each primer, 10 ml bisul®te-treated DNA and 5 u Taq (Promega). Primers and parameters were: 5'-TATTGTTTTTTAAGTTAAGTTGTTGTAAA-3' (sense) and 5'-AAAAAAATTC-TAATCCCCCCTTTAA-3' (antisense); 948C for 5 min; 40 cycles of 948C for 1 min, 488C for 1 min, 728C for 1.5 min; 728C for 5 min. Second round: 5'-GTGAGTTAGGAGTAGTGTTTTGGTTTTTTTTT-3' (sense) and 5'-CTTTAACAAAAAA-TAAACCCTCCTAA-3' (antisense); parameters as above but 20 cycles instead of 40. The puri®ed PCR fragment was subcloned into the pCR2.1 vector and individual clones submitted for sequencing. (c) Sequencing pro®le of the b2 promoter in MCF-7 clone I. Anti-parallel bisul®te modi®ed sequence is shown; bold line shows G residues, indicative of methylated, non-modi®ed C. Arrow heads indicate methylation-susceptible cytosines; TATA box and direct repeats shown for orientation. (d) Bisul®te sequencing of the 5'-UTR region (sense strand). Semi-nested PCR of bisul®te modi®ed RARb2 DNA was carried out with the same ®rst primer as above and 5'-ATCCAACCAAAACAAAAAATTCCCAAAAAA-3' antisense primer and, for second round, 5'-AAAATGTTGGTTTGTGTGTTTGTTG-3' sense primer. Parameters were as before but annealing temperatures were 528C (®rst round) and 548C (second round). The RARE was also ampli®ed by these primers and the results con®rmed those in b Figure 3 Eect of 5-azacytidine on RARb2 expression. (a) Exponentially growing MCF-7 cells were pretreated or not with 5 (lane 3) or 10 mM (lane 4) azaC for 2 days then treated as shown for 24 h (RA at 1 mM, TSA at 100 nM). For RT ± PCR Southern, 2 mg total RNA were reverse transcribed and 10% cDNA was ampli®ed in a mixture of 106 PCR Buer, 1 mM MgCl 2 , 200 mM dNTPs, 0.4 mM each primer and 5 u Taq (Promega) in a total volume of 50 ml. Primers and cycling parameters were: for RARb2: 5'-CCACACCTAGAGGATAAGCACT-3' (sense; exon 3) and 5'-GTGGTACCCTGATGATTTGTCC-3' (antisense; exon 4); 948C for 5 min; 32 cycles of 948C for 1 min, 588C for 1 min, 728C for 1 min; 728C for 5 min. For GAPDH: 5'-TCATCATCTCTGCCC-CCTCT-3' (sense; exon 5) and 5'-TCCGACGCCTGCTTCACCAC-3' (antisense; exon 7); parameters as above except that for 20 cycles. Preliminary experiments established proportionality between RNA input (0.5, 1, 2 and 4 mg) and ampli®cation product (data not shown). Southern blots were probed with hRARb2 or GAPDH cDNA and autoradiographed for 2 h. (b) Exponentially growing MDA-MB-231 A2 or A4 cells were pretreated with 7.5 mM azaC where indicated then treated as for MCF-7 cells. RT ± PCR Southern was as above. Blots were autoradiographed for 45 min (Mira-y-Lopez, 1991) were transiently co-transfected with 40 ml of WT, in vitro methylated (ME) or MUT RARE-TKGH ligation mix (see below) and 0.1 mg pRLSV40, then washed and treated with 1 mM RA for 24 h. GH levels in the medium were normalized to Renilla LUC. Similar results were obtained in a second experiment. The RARE was methylated with SssI CpG methylase and S-adenosylmethionine (New England Biolabs, USA); digestion with HpaII and denaturing polyacrylamide gel electrophoresis indicated that *50% of the RARE was methylated (data not shown). Forty pmols of phosphorylated RARE (WT, ME or MUT) oligo was ligated at a 1 : 1 molar ratio to HindIII-linearized and dephosphorylated pTKGH (Nichols Institute Diagnostics) in a total volume of 300 ml. Cells were directly transfected with each ligation mixture since ampli®cation in E. coli would not have maintained the methylation pattern generated in vitro. Agarose gel electrophoresis indicated that similar amounts of the desired ligation product were generated using the dierent RARE oligos (data not shown). (c) SC115 cells were co-transfected with 20 ml of ligation mix (*9 mg DNA) and 0.9 mg pSV2neo and selected in 400 mg/ml G418 medium. Cells were then treated as shown (RA at 1 mM, TSA at 100 nM) for 24 h; GH levels were normalized to total cell protein. Similar results were obtained in two additional experiments. (d) G418-resistant cells were plated at low density and single colonies picked and expanded. SC115 clones displaying low transgene copy number were treated with 1 mM RA for 24 h and the fold stimulation in GH levels expressed in a log scale. Clones with high constitutive reporter activity (log pg GH44) responded poorly to RA and were excluded; 1/7 WT and 4/13 MUT RARE clones were in this category. The mean constitutive log pg GH values for the clones shown were 2.7 (WT) and 2.4 (MUT RARE). Clones with undetectable constitutive activity were also excluded as it was not possible to calculate the fold stimulation by RA; 1/7 WT and 1/13 MUT RARE clones were in this category activated (Figure 4d) . The dierence between the two groups was statistically signi®cant by Student's t-test (P50.02) and Mann-Whitney's test (P50.02). We infer from these ®ndings that methylation of the b2 RARE may likewise hinder its activation when in the context of chromatin.
Our results suggest that methylation of the CpG sites in the MCF-7 b2 RARE plays an important role in RARb2 silencing in these cells. Thus, we showed that these sites (especially sites 2 and 3) were methylated in the endogenous MCF-7 b2 promoter but not in the endogenous, transcriptionally active MTSV1.7 b2 promoter. Further, azaC in combination with TSA and RA rescued RARb2 expression in MCF-7 cells but not in MDA-MB-231 A4 cells, in which the b2 RARE was not methylated (Figure 3) . On the other hand, methylation of the MCF-7 b2 RARE was not uniform and we did not analyse the 5'-UTR or the 5'-¯anking region. Indeed, while this report was in preparation, methylation of both of these regions in MCF-7, other breast cancer cells and breast cancer tissue was demonstrated using methylation sensitive PCR (Sirchia et al., 2000) . Moreover, in contrast to our results for MDA-MB-231 clone A4 cells, treatment with 5-aza-2'-deoxycytidine increased receptor expression in parental MDA-MB-231 cells (Sirchia et al., 2000) . The relative contribution that methylation of the RARE makes to RARb2 silencing needs to be addressed further. This is a point of interest because, much as we have shown here for MCF-7 and MDA-MB-231 A4 cells, there appears to be variation in b2 RARE methylation from one breast tumor to another, whereas methylation of the 5'-UTR may be less variable (Bovenzi et al., 1999) . We infer from the results we obtained using the mutant b2 RARE in the context of an embedded heterologous promoter that, at least in this context, RARE methylation may have a similar eect. If so, then RARE methylation may be sucient to impair RARb2 transcription. Figure 3b suggests that a mechanism other than gene methylation contributes to RARb2 silencing in MDA-MB-231 clone A4 cells. This is in agreement with recent data by Widschwendter et al. for grade III breast tumors and BT20 cells [(2000) J. Natl. Cancer Inst., 92, 826 ± 832] . Upon bisul®te sequencing, we found that the RARb2 5'-UTR is densely methylated in BT20 cells and that the RARE is also methylated, albeit less densely (comparable to MCF-7; data not shown). Thus, even RARE methylation is poorly correlated with RARb2 silencing in poorly dierentiated tumors.
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